

# Research Article

# Magnitude of Thrombocytopenia and Associated Factors among Pregnant Women Attending the Antenatal Care Service Unit of Wachemo University Nigist Ellen Mohammed Comprehensive Specialized Hospital Hosanna, Southern Ethiopia

# Dembelo Tirago,<sup>1</sup> Tilahun Yemane,<sup>2</sup> and Edosa Tadasa <sup>2</sup>

<sup>1</sup>Department of Medical Laboratory Science, Hossana Health Science College, Hosanna, Ethiopia <sup>2</sup>School of Medical Laboratory Sciences, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia

Correspondence should be addressed to Edosa Tadasa; edosatadasa10@gmail.com

Received 4 September 2023; Revised 27 February 2024; Accepted 28 March 2024; Published 16 April 2024

Academic Editor: Manishekhar Kumar

Copyright © 2024 Dembelo Tirago et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Thrombocytopenia is the second most common hematological disorder in pregnancy after anemia worldwide and affects 7-8% of all pregnancies. Pregnant women with thrombocytopenia have complications of excessive bleeding during or after childbirth, exudation at the cesarean section, and neonatal thrombocytopenia. Therefore, the main aim of this study was to assess the magnitude of thrombocytopenia and its associated factors among pregnant women attending the Antenatal Care Service Unit of Wachemo University Nigist Ellen Mohammed Comprehensive Specialized Hospital Hosanna, Southern Ethiopia. Materials and Methods. A cross-sectional study was conducted from June 1 to August 30, 2022, involving 209 consecutive pregnant women who came to the hospital during the study period for antenatal care follow-up. Sociodemographic, reproductive, and other clinical data were collected using a structured questionnaire. A four-milliliter venous blood specimen was collected for complete blood analysis and peripheral blood smear. The data were analyzed by using SPSS version 25. Descriptive statistical analysis and bivariate and multivariate logistic regression analyses were performed. A P value  $\leq 0.05$  was considered to indicate statistical significance. Results. The overall magnitude of thrombocytopenia among pregnant women was 14.8% (95% CI: 10, 19.6). The prevalence of mild, moderate, and severe thrombocytopenia was 77.4%, 16.1%, and 6.5%, respectively. Multivariate logistic regression revealed that rural residence (AOR = 2.6 and 95% CI = 1.02, 7.12), cigarette smoking (AOR = 8.4 and 95% CI = 1.86, 38), anemia (AOR = 8.3 and 95% CI = 2.7, 25.6), and alcohol consumption (AOR = 8.2 and 95% CI = 2.17-31) were significantly independent factors associated with the development of thrombocytopenia. Conclusion. The magnitude of thrombocytopenia in this study was 14.8%. Rural residence, cigarette smoking, alcohol consumption, and anemia were significantly associated with thrombocytopenia. Therefore, the platelet count should be routinely determined during antenatal care visits for proper diagnosis and to minimize bleeding during and/or after childbirth.

# 1. Introduction

Thrombocytopenia is a common hematologic abnormality and is defined as a platelet count less than  $150 \times 10^9$ /L. However, many consider a cutoff value of  $100 \times 10^9$ /L to be more appropriate for identifying clinically significant thrombocytopenia [1, 2]. Thrombocytopenia is the second most common hematological abnormality during pregnancy after anemia. It occurs in 7-8% of all pregnancies [3, 4]. Platelets are anucleate cell fragments of megakaryocytes that play an important role in hemostasis. They arise from the fragmentation of megakaryocytes, bone marrow cells with high polyploidy that arise through the process of mitosis and endomitosis [5]. After leaving the marrow space, approximately one third of the platelets are sequestered in the spleen, and the remaining two thirds circulate for 7–10 days. Typically, only a small portion of the platelet mass is used in the process of hemostasis, so

most platelets circulate until they age and are removed by phagocytic cells. The normal platelet count is between 150 and  $450 \times 10^9/l$  [6].

The severity of thrombocytopenia was divided into 3 grades depending on the PLT: mild thrombocytopenia with a PLT between 100 and  $150 \times 10^9$ /l and moderate thrombocytopenia with a PLT between 50 and  $100 \times 10^9$ /l. Severe thrombocytopenia was defined as a level less than  $50 \times 10^9$ /L [5]. The American Society of Hematology requires that treatment be initiated if the PLT is less than  $30 \times 10^9$ /L or if bleeding occurs between the 2nd and 3rd trimesters of pregnancy [4].

The PLT during pregnancy varies depending on the trimester and gradually decreases from the first trimester until delivery. The physiological causes of thrombocytopenia include an increase in plasma volume (dilution effect), accumulation of platelets in the spleen due to spleen enlargement during pregnancy, and accumulation of platelets in the intervillous space of the placenta [7, 8].

Thrombocytopenia can be caused by decreased bone marrow production, increased splenic sequestration, or accelerated platelet destruction. During pregnancy, most cases are due to increased destruction of platelets, which may be caused by the immune system, abnormal activation of platelets, or consumption of platelets due to exposure to abnormal vessels or excessive bleeding. Reduced platelet production during pregnancy occurs less frequently and is usually associated with bone marrow disorders or nutritional deficiencies [1, 6]. Pregnant women with low platelet counts tend to be much less symptomatic due to the procoagulant state caused by elevated levels of factor VIII, fibrinogen, and von Willebrand factor (VWF); suppressed fibrinolysis; and reduced protein S activity [9].

Thrombocytopenia during pregnancy can have various causes. Some of these associations are pregnancy specific, while others can occur outside of pregnancy. These include gestational thrombocytopenia, hypertensive disorders of pregnancy and hemolysis, elevated liver enzymes and low platelet count syndrome (HELLP), liver disease (acute fatty liver of pregnancy), drug-induced thrombocytopenia, immune thrombocytopenic purpura, virus-induced thrombocytopenia, disseminated intravascular coagulation (DIC), hemolytic uremic syndrome (HUS), vitamin B12 and folic acid deficiency, and myelopthisis [10, 11].

Immune thrombocytopenic purpura (ITP) is caused by platelet autoantibodies against various glycoprotein complexes of the platelet membrane and is responsible for approximately 5% of the cases of thrombocytopenia during pregnancy [12]. Pregnant women with hypertension account for 5–21% of the cases of maternal thrombocytopenia [13]. Preeclampsia (PE) and HELLP syndrome are considered to be the cause of thrombocytopenia during pregnancy in approximately 14.2% of the cases [12]. All pregnant women with a PLT less than  $100 \times 10^9$ /L require detailed hematological and obstetric consultation to rule out more serious conditions [14]. In sub-Saharan Africa, the prevalence is slightly higher at 15.3%. This condition is responsible for up to 10% of the cases of postpartum hemorrhage in developing countries, with a maternal mortality rate of 5.26% [15, 16].

Hematologic changes during pregnancy are common and can result in maternal and fetal morbidity [7]. Approximately 8–10% of pregnant women, especially in the third trimester, are affected by thrombocytopenia and 75% of these cases are due to the benign process of gestational thrombocytopenia [17]. It is often associated with an increased risk of bleeding before and after birth, particularly during cesarean section or other surgical procedures during pregnancy [4, 18].

The most common cause of gestational thrombocytopenia (GT) is thrombocytopenia during pregnancy, which commonly occurs in 5–11% of pregnant women [19]. It is typically an incidental diagnosis, and the pathogenesis of this disease is unclear [20].

Thrombocytopenia during pregnancy results in additional, often invasive and unnecessary, examinations and a cesarean section. Pregnant women with thrombocytopenia experience complications such as excessive bleeding during or after delivery, cesarean section discharge, stillbirths, and neonatal thrombocytopenia. Examination and treatment of this condition can be expensive, painful, and potentially undesirable for the patient [18]. In Ethiopia, particularly in selected study area complete blood counts are routinely performed for all pregnant women. However, there is no follow-up on platelet count during third trimester, labour, and delivery until severe complications were ensured. Determining magnitude of thrombocytopenia severity and associated factors plays a great role in the management of thrombocytopenic women and is important to develop evidence-based intervention measures, which are not well known in this study area. Therefore, the aim of this study was to evaluate the magnitude of thrombocytopenia and its associated factors during pregnancy at Nigist Ellen Mohammed Memorial Comprehensive Specialized Hospital, Wachemo University.

## 2. Materials and Methods

2.1. Study Design, Area, and Period. A hospital-based crosssectional study was conducted from June 1 to August 30, 2022, at Wachemo University Nigist Ellen Mohammed Memorial Comprehensive Referral Hospital (WUNEMMCSH), which is located in Hosanna Town, Hadiya Zone, Southern Nations Nationalities, and People's Region (SNNPR). The town is 232 km from the capital city of Addis Ababa to the southwest and 157 km from the regional city of Hawassa. The town lies on average 2,177 m above the sea level. This hospital was established in the 1976 EC, and its catchment area population is estimated to be approximately 3,476,386. On average, 1244 pregnant women attended the hospital annually. The study was conducted in an antenatal care clinic.

2.2. Study Population. All pregnant women aged between 15 and 49 years who attended the WUNEMCSH antenatal care service clinic during the study period and met the inclusion criteria were included. Study participants who took medications such as heparin and nonsteroidal antiinflammatory drugs such as aspirin and had bleeding disorders, splenomegaly, or chronic illness (HCV, HBV, or hypertension) were excluded from the study after reviewing their medical records.

2.3. Sample Size Determination and the Sampling Technique. The sample size was calculated by using the single population proportion formula by taking the 14.5% prevalence of thrombocytopenia [21] and by considering a 95% confidence interval (CI) and 5% margin of error. The final sample size after adding a 10% nonresponse rate was 209. All pregnant women who attended the WUNEMCSH antenatal care service clinic during the study period were consecutively included in the study until attaining the final sample size.

2.4. Data Collection Methods and Instruments. Data on sociodemographic characteristics and clinical and other related factors were collected by trained data collectors. After the purpose of the study was explained, a laboratory technologist collected 4 mL of venous blood from each study participant into tubes containing ethylenediaminetetraacetic acid (EDTA) for complete blood count analysis and blood smear preparation. Platelet counts, platelet parameters, and other hematological parameters were measured using a MINDRAY BC-3000 PLUS automated hematology analyzer (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., China). Thin blood smears were prepared from thrombocytopenic specimens, air-dried, labeled, and stained with Wright's stain to assess platelet morphology (small platelets and giant platelets) and the presence of malaria parasites. In addition, platelet aggregation was observed to distinguish between pseudo thrombocytopenia and true thrombocytopenia.

Thrombocytopenia is said to be present when the platelet count of the pregnant women is less than  $150 \times 10^9$ /L. The PLT count between 100 and  $150 \times 10^9$ /l is considered mild thrombocytopenia, levels ranging between 50 and  $100 \times 10^9$ /l are considered as moderate thrombocytopenia, and levels less than  $50 \times 10^9$ /L are considered as severe thrombocytopenia [22].

2.5. Data Quality Control. The quality of the data was guaranteed by implementing quality control (QC) measures throughout the whole process of the laboratory work, data collection, data entry, and data processing. The quality of the data was maintained by pretesting the questionnaire before the actual data collection. MINDRAY BC-3000 PLUS hematology analyzer was checked for linearity and validity of the results by analyzing whole-blood quality control material (high, normal, and low). The quality of the blood specimens was maintained during sample collection, transportation, and processing by mixing an appropriate volume of blood and anticoagulant following the standard operating procedure at each step and analyzing the samples within time. All reagents were checked for their expiration date and prepared according to the manufacturer's instructions. Wright stains were filtered every day by using filter paper and stored in locked cabinets away from moisture and sunlight. In addition, thin blood films prepared from thrombocytopenic clients and stained with Wright stain were examined to confirm the presence of platelet aggregation, which was used to differentiate true thrombocytopenia from pseudothrombocytopenia.

2.6. Data Processing and Analysis. The data collected for the study were cleaned, entered into Epi Data version 4.6, and analyzed using the Statistical Package for Social Science (SPSS) version 25 (IBM Corporation, Chicago, USA). Descriptive statistics, frequency tables, graphs, and logistic regression were used to describe the study variables and to determine the impact of the independent variables on the prevalence of thrombocytopenia. Bivariate analysis was performed to select candidate variables for multivariate analysis, and variables with a P value <0.25 were selected as candidates. Multivariate logistic regression analysis was used to identify risk factors associated with thrombocytopenia, 95% confidence intervals were calculated, and a P value of 0.05 or less was used to indicate statistical significance.

2.7. Ethical Clearance. Ethical clearance was obtained from the Institutional Review Board (IRB) of the Institute of Health, Jimma University (letter number IRB000843/2022; date, April 30/2022). Permission to conduct the study was obtained from the Wachemo University Nigist Ellen Mohammed Comprehensive Specialized Hospital. All study participants were made aware of the study's purpose, risks, and benefits, and their written informed consent was obtained from each participant before they took part in the study per the Declaration of Helsinki and universal Good Clinical and Laboratory Practice (GCP and GCLP) principles. Patient confidentiality, equity of services, and patient interests were ensured during the study period. All data collected during the study were treated with strict confidentiality and used only for this study.

#### 3. Results

3.1. Sociodemographic Characteristics of the Study Participants. A total of 209 pregnant women were included in this study with a response rate of 100%. The mean (±SD) age of the study participants was  $26.1 \pm 4.983$  years (age ranged from 17 to 43). About 61.2% (n = 128) of the study participants were urban area residents. The majority (85.6%; n = 179) of the participants were married. Among the study participants, about 33.5% (n = 70) were in primary school, and 56.5% (n = 118) were housewives (Table 1).

3.2. Reproductive, Clinical, and Other Characteristics of the Study Participants. The mean (±SD) gestational age of the study participants was  $26.94 \pm 7.63$  weeks (gestational age ranged from 8 to 41). The majority (52.6%, n = 110) of the study participants were in the third trimester. About 49.8% (n = 104) of the study participants had previously undergone ANC follow-up. Among the study participants, about 24.4% (n = 51) had a history of heavy menstrual bleeding, and 14.4% (n = 30) had hemoglobin levels less than 11 g/dl (Table 2).

Variables	Categories	Frequency	Percentage (%)
	15-24	58	27.8
Age in year 25–34		131	62.7
0	≥35	20	9.6
D :1	Urban	128	61.2
Residence	Rural	81	38.8
	Single	12	5.7
Manifal status	Married	179	85.6
Marital status	Divorced	8	3.8
	Widowed	10	4.8
	Illiterate	27	12.9
Primary school		70	33.5
Educational status	Educational status Secondary school		32.1
	College/University and above	45	21.5
	Farmer	6	2.9
	Daily laborer	1	0.5
	Employee	40	19.1
Occupational status	Students	29	13.9
	Merchants	15	7.2
	Housewife	118	56.5
	≤1500	159	76.1
Monthly income in ETB* >1500		50	23.9

TABLE 1: Sociodemographic characteristics of pregnant women attending antenatal care clinics at Wachemo University Nigist Ellen Mohammed Comprehensive Specialized Hospital Hosanna, Southern Ethiopia, from June to August 30, 2022.

ETB\* Ethiopian birr, Employee+, governmental employee.

TABLE 2: Reproductive, clinical, and other related characteristics of pregnant women attending antenatal care clinics at Wachemo University Nigist Ellen Mohammed Comprehensive Specialized Hospital Hosanna, Southern Ethiopia, from June to August 30, 2022.

Variables	Categories	Frequency	Percentage (%)
	First trimester	8	3.8
Gestational age	Second trimester	91	43.5
-	Third trimester	110	52.6
Progrant bafara	Yes	130	62.2
rieghant before	No	79	37.8
	No children	4	3.1
Number of children	1	22	16.9
Number of children	2	45	34.6
	3 and above	Frequency         Percenta           8         3.4           91         43           110         52           130         62           79         37           4         3.           22         16           45         34           59         45           104         49           105         50           51         24           158         75           71         34           138         66           99         47           110         52           26         26           30         30           43         43           107         51           102         48           30         14           179         85           180         86           29         13	45.4
ANC follow up in a provious program of	Yes	FrequencyPercent83.91431105213062793743.2216453459451044910550512415875713138699471105226263030434310751102482511848301417985180862913	49.8
ANC follow-up in a previous pregnancy	No	105	50.2
Ilisten of herein mentional blacking	Yes	es         rrequency         Percent           ester         8         3.           nester         91         43           ester         110         52           130         62           79         37           ren         4         3.           22         16           45         34           ove         59         45           104         49           105         50           51         24           158         75           71         3           138         6           99         47           110         52           26         26           ven         30         30           107         51           102         48           25         1           184         8           11         30         14           11         179         85           180         86         29         13	24.4
History of neavy menstrual bleeding	No	158	75.6
Histomy of shouting	Yes	71	34
history of abortion	No	138	66
II: to me of a sector continue of the sector	Yes	99	47.4
History of contraceptive usage	No	110	52.6
	Oral	26	26.3
Types of contraceptives used	CategoriesFrequencyPerFirst trimester8Second trimester91Third trimester110Yes130No79No children41222453 and above59Yes104No105Yes51No158Yes71No138Yes99No110Oral26Depoproven30Norplant43Yes107No102Yes25No184<11 g/dl	30.3	
	Norplant	43	43.4
Inon on folio acid supplementation	Yes	FrequencyPercent8391431105213062793743221645345945104491055051241587571313869947110522626303043431075110248301417985180862913	51.2
from or fonc acid supplementation	No	102	48.2
Ilistana ef melocie	Yes	25	12
History of malaria	No	184	88
IIah laval in a/dl	<11 g/dl	30	14.4
ngo ievel ili g/di	$\geq 11 \text{ g/dl}$	179	85.6
Consumption of animal products including most	Yes	180	86.1
Consumption of animal products including meat	No	29	13.9

Variables	Categories	Frequency	Percentage (%)	
	Daily	3	1.7	
There are not the set of the set of the size of the set	Every 2 day	14	14	
How many times eat meat and animal products	Every weekly	53	29.4	
	Once a month	110	61.1	
	Yes	205	98.1	
Eat fruit and vegetables	No	4	1.9	
	Daily	16	7.8	
II	Every 2 day	50	24.4	
How many times eat truit and vegetables	Every weekly	133	64.9	
	Once a month	6	2.9	
	Yes	179	85.5	
A habit of drinking conee or tea immediately after a meai	No	30	14.4	
	Yes	18	8.6	
Cigarette smoking	No	191	91.4	
	Yes	22	10.5	
Alconol consumption	No	187	89.5	
	<23	114	54.5	
MUAC in cm	≥23	95	45.5	

TABLE 2: Continued.

3.3. Magnitude and Severity Pattern of Thrombocytopenia among Study Participants. The mean (±SD) platelet count among the study participants was  $234.1 \pm 96.1 \times 10^9$ /L. The overall magnitude of thrombocytopenia among the study participants was 31 (14.8%), with a 95% CI of 10 (19.6). Among thrombocytopenic study participants, 24 (77.4%), 5 (16.1%), and 2 (6.5%) had mild, moderate, and severe thrombocytopenia, respectively (Figure 1).

Among the study participants, the proportion of thrombocytopenia was 19.9% (n = 16) in rural residences, 15.7% (n = 11) in primary school, 33.3% (n = 6) in smoking cigarettes, 50% (n = 11) in alcohol consumption, 46.7% (n = 14) among hemoglobin level less than 11 g/dl, 48.4% (n = 15) within gestational age of third trimester, and 64.5% (n = 20) among study participant within the age group of 25–34 years. Among those with a history of malaria infection, 24% had thrombocytopenia and 33.3% had thrombocytopenia among smoking cigarette participants (Table 3).

Among the study participants, 12% (n=1), 16.5% (n=15), and 13.6% (n=15) of the participants had thrombocytopenia in different trimesters/gestational ages, first trimester, second trimester, and third trimester, respectively, with 95% CI (10, 19.6) (Table 3).

Thin blood films were prepared from thrombocytopenic clients, and Wright staining was used to confirm the presence of platelet aggregation, satelitism, and the presence of the malaria parasite. The commonest blood picture indicates that there was no hemiparasite, platelet aggregation, or platelet satelitism in the blood film.

3.4. Factors Associated with Thrombocytopenia in the Study Participants. According to our bivariate analysis, rural residence, educational status, previous ANC follow-up, history of malaria, eating meat or animal products, smoking cigarette habit, alcohol consumption, hemoglobin level, and

Severity of Thrombocytopenia



FIGURE 1: Severity pattern of thrombocytopenia among pregnant women at Wachemo University Nigist Ellen Mohammed Comprehensive Specialized Hospital Hosanna, Southern Ethiopia, from June to August 30, 2022.

middle upper arm circumference (MUAC) were identified as candidate variables associated with thrombocytopenia multivariate analysis by considering P value <0.25 (Table 3).

3.5. Multivariate Logistic Regression Analysis of Factors Associated with Thrombocytopenia. The variable included in the final logistic regression analysis was rural residence; smoking, alcohol consumption, and hemoglobin level were significantly associated with thrombocytopenia (Table 4).

The odds of being were thrombocytopenic approximately 3 times higher among rural residents than among urban residents (AOR = 2.6, 95% CI = 1.02, 7.12, and P = 0.045). The adjusted odds ratio (OR) revealed that pregnant women who smoked cigarettes were 8 times more likely to be

TABLE 3: Bivariate analysis of factors associated with thrombocytopenia among pregnant women attending antenatal care clinics at Wachemo University Nigist Ellen Mohammed Comprehensive Specialized Hospital Hosanna, Southern Ethiopia, from June to August 30, 2022.

x7 · 11		Thrombocytopenia		COD 0504 CI	D 1
variables	Categories	No (%)	Yes (%)	a         COR 95% CI $(\%)$ 1 $5.5\%$ 1 $5.3\%$ 1.65 (0.32, 8.39) $0\%$ 1.62 (0.34, 7.5) $1.7\%$ 1 $9.9\%$ 1.85 (0.86, 3.99) $1.1\%$ 038 (0.09, 1.53) $15.7$ 0.57 (0.22, 1.47) $9\%$ 0.10 (0.10, 0.89) $24.4$ 1 $3.8\%$ 0.732 (0.31, 1.71) $8\%$ 1 $2\%$ 1 $5.5\%$ 0.73 (0.10, 7.8) $3.6\%$ 1.25 (0.57, 2.7) $3.3\%$ 1 $1.4\%$ 0.57 (0.26, 1.26) $6.9\%$ 1.24 (0.58, 2.79) $3.8\%$ 1 $4.1\%$ 0.91 (0.41, 1.93) $15.5$ 1 $14\%$ 0.57 (0.26, 1.26) $6.9\%$ 1.24 (0.58, 2.79) $3.8\%$ 1 $1.1\%$ 0.87 (0.40, 1.88) $3.3\%$ 1 $1.41\%$ 0.91 (0.41, 1.93) $15.5$ 1 <td>P value</td>	P value
	15-24	49 (84.5)	9 (15.5%)	1	
Variables Age in year Residence Educational status Monthly income in ETB* Gestational age in a week Previously ANC follow-up History of abortion History of abortion History of contraceptive usage Taken iron and folic acid supplement Eat meat and animal product History of malaria Smoking cigarette habit	25-34	111 (84.4%)	20 (15.3%)	1.65 (0.32, 8.39)	0.544
	≥35	18 (90%)	2 (10%)	$\begin{array}{c} \text{COR 95\% CI} \\ \hline 1 \\ 1.65 (0.32, 8.39) \\ 1.62 (0.34, 7.5) \\\hline 1 \\ 1.85 (0.86, 3.99) \\\hline 038 (0.09, 1.53) \\\hline 0.757 (0.22, 1.47) \\\hline 0.10 (0.10, 0.89) \\\hline 1 \\\hline 0.732 (0.31, 1.71) \\\hline 1 \\\hline 0.73 (0.10, 7.8) \\\hline 1.25 (0.57, 2.7) \\\hline 1 \\\hline 0.57 (0.26, 1.26) \\\hline 1.24 (0.58, 2.79) \\\hline 1 \\\hline 0.91 (0.41, 1.93) \\\hline 1 \\\hline 0.91 (0.41, 1.93) \\\hline 1 \\\hline 0.87 (0.40, 1.88) \\\hline 1 \\\hline 2.06 (0.79, 5.36) \\\hline 2.0 (0.73, 5.51) \\\hline 1 \\\hline 1 \\\hline 3.32 (1.14, 9.64) \\\hline 1 \\\hline 0.12 (0.46, 0.31) \\\hline 1 \\\hline 1 \\\hline 8.33 (3.47, 19.98) \\\hline 1 \\\hline 1.62 (0.73, 3.58) \\\hline 1 \\\hline \end{array}$	0.537
Desidence	Urban	113 (88.3%)	15 (11.7%)	1	
Residence	Rural	65 (80.2%)	16 (19.9%)	1.85 (0.86, 3.99)	0.115
	Illiterate	24 (88.9%)	3 (11.1%)	038 (0.09, 1.53)	0.177
Educational status	Primary school	59 (84.3)	11 (15.7)	0.57 (0.22, 1.47)	0.249
Educational status	Secondary school	61 (9%)	6 (9%)	0.10 (0.10, 0.89)	0.031
	College/university and above	34 (75.6%)	11 (24.4)	1	
Monthly in some in ETD*	≤1500	137 (86.2%)	22 (13.8%)	0.732 (0.31, 1.71)	0.479
Monuny income in ETB	>1500	41 (82%)	9 (18%)	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
	First trimester	7 (87.5%)	1 (12%)	1	
Gestational age in a week	Second trimester	76 (83.5%)	15 (16.5%)	0.73 (0.10, 7.8)	0.471
	Third trimester	95 (86.4%)	15 (13.6%)	1.25 (0.57, 2.7)	0.573
	Yes	85 (81.7%)	19 (18.3%)	1	
Previously ANC follow-up	No	93 (88.6%)	12 (11.4%)	0.57 (0.26, 1.26)	0.168
	Yes	59 (83.1%)	12 (16.9%)	1.24 (0.58, 2.79)	0.547
History of abortion	No	119 (86.2)	19 (13.8%)	1	
	Yes	85 (85.9)	14 (14.1%)	0.91 (0.41, 1.93)	0.79
History of contraceptive usage	No	93 (84.5)	17 (15.5)	COR 95% CI 1 1.65 (0.32, 8.39) 1.62 (0.34, 7.5) 1 1.85 (0.86, 3.99) 038 (0.09, 1.53) 0.57 (0.22, 1.47) 0.10 (0.10, 0.89) 1 0.732 (0.31, 1.71) 1 0.73 (0.10, 7.8) 1.25 (0.57, 2.7) 1 0.57 (0.26, 1.26) 1.24 (0.58, 2.79) 1 0.57 (0.40, 1.88) 1 0.91 (0.41, 1.93) 1 0.87 (0.40, 1.88) 1 2.06 (0.79, 5.36) 2.0 (0.73, 5.51) 1 3.32 (1.14, 9.64) 1 0.12 (0.46, 0.31) 1 8.33 (3.47, 19.98) 1 1.62 (0.73, 3.58) 1	
The inclusion of falls and second second	Yes	92 (86%)	15 (14%)	$\begin{array}{c} \text{COR 95\% CI} \\ 1 \\ 1.65 (0.32, 8.39) \\ 1.62 (0.34, 7.5) \\ 1 \\ 1.85 (0.86, 3.99) \\ 038 (0.09, 1.53) \\ 0.57 (0.22, 1.47) \\ 0.10 (0.10, 0.89) \\ 1 \\ 0.732 (0.31, 1.71) \\ 1 \\ 0.732 (0.31, 1.71) \\ 1 \\ 0.73 (0.10, 7.8) \\ 1.25 (0.57, 2.7) \\ 1 \\ 0.57 (0.26, 1.26) \\ 1.24 (0.58, 2.79) \\ 1 \\ 0.91 (0.41, 1.93) \\ 1 \\ 0.91 (0.41, 1.93) \\ 1 \\ 0.87 (0.40, 1.88) \\ 1 \\ 2.06 (0.79, 5.36) \\ 2.0 (0.73, 5.51) \\ 1 \\ 1 \\ 0.12 (0.46, 0.31) \\ 1 \\ 1 \\ 0.12 (0.46, 0.31) \\ 1 \\ 1 \\ 8.33 (3.47, 19.98) \\ 1 \\ 1.62 (0.73, 3.58) \\ 1 \\ 1 \end{array}$	
Taken from and folic acid supplement	No	86 (84.3%)	16 (15.7%)		0.73
	Yes	156 (86.7)	24 (13.3%)	$\begin{array}{c} \text{COR 95\% CI} \\ 1 \\ 1.65 (0.32, 8.39) \\ 1.62 (0.34, 7.5) \\ 1 \\ 1.85 (0.86, 3.99) \\ 038 (0.09, 1.53) \\ 0.57 (0.22, 1.47) \\ 0.10 (0.10, 0.89) \\ 1 \\ 0.732 (0.31, 1.71) \\ 1 \\ 0.732 (0.31, 1.71) \\ 1 \\ 0.73 (0.10, 7.8) \\ 1.25 (0.57, 2.7) \\ 1 \\ 0.57 (0.26, 1.26) \\ 1.24 (0.58, 2.79) \\ 1 \\ 0.57 (0.26, 1.26) \\ 1.24 (0.58, 2.79) \\ 1 \\ 0.91 (0.41, 1.93) \\ 1 \\ 0.91 (0.41, 1.93) \\ 1 \\ 0.87 (0.40, 1.88) \\ 1 \\ 2.06 (0.79, 5.36) \\ 2.0 (0.73, 5.51) \\ 1 \\ 3.32 (1.14, 9.64) \\ 1 \\ 0.12 (0.46, 0.31) \\ 1 \\ 1 \\ 8.33 (3.47, 19.98) \\ 1 \\ 1.62 (0.73, 3.58) \\ 1 \\ \end{array}$	
Eat meat and animal product	No	22 (75.9%)	7 (24.1%)	2.06 (0.79, 5.36)	0.135
	Yes	19 (76%)	6 (24%)	2.0 (0.73, 5.51)	0.176
History of malaria	No	159 (86.4%)	25 (13.6%)	1	
Conclaiment air and the habit	Yes	12 (66.7%)	6 (33.3%)	3.32 (1.14, 9.64)	0.027
Smoking cigarette nabit	No	166 (86.9%)	25 (13.1%)	$\begin{array}{c ccccc} 0.13.70 & 0.73 & (0.10, 7.8) \\ \hline 5 & (13.6\%) & 1.25 & (0.57, 2.7) \\ \hline 9 & (18.3\%) & 1 \\ \hline 2 & (11.4\%) & 0.57 & (0.26, 1.26) \\ \hline 2 & (16.9\%) & 1.24 & (0.58, 2.79) \\ \hline 9 & (13.8\%) & 1 \\ \hline 4 & (14.1\%) & 0.91 & (0.41, 1.93) \\ \hline 17 & (15.5) & 1 \\ \hline 15 & (14\%) & 1 \\ \hline 6 & (15.7\%) & 0.87 & (0.40, 1.88) \\ \hline 4 & (13.3\%) & 1 \\ \hline 7 & (24.1\%) & 2.06 & (0.79, 5.36) \\ \hline 6 & (24\%) & 2.0 & (0.73, 5.51) \\ \hline 5 & (13.6\%) & 1 \\ \hline 5 & (13.1\%) & 1 \\ \hline 11 & (50\%) & 0.12 & (0.46, 0.31) \\ \hline 0 & (10.7\%) & 1 \\ \end{array}$	
	Yes	11 (50%)	11 (50%)	0.12 (0.46, 0.31)	< 0.001
Alcohol consumption	No	167 (89.3%)	20 (10.7%)	$\begin{array}{c} \text{COR 95\% CI} \\ 1 \\ 1.65 (0.32, 8.39) \\ 1.62 (0.34, 7.5) \\ 1 \\ 1.85 (0.86, 3.99) \\ 038 (0.09, 1.53) \\ 0.57 (0.22, 1.47) \\ 0.10 (0.10, 0.89) \\ 1 \\ 0.732 (0.31, 1.71) \\ 1 \\ 0.732 (0.31, 1.71) \\ 1 \\ 0.73 (0.10, 7.8) \\ 1.25 (0.57, 2.7) \\ 1 \\ 0.57 (0.26, 1.26) \\ 1.24 (0.58, 2.79) \\ 1 \\ 0.57 (0.26, 1.26) \\ 1.24 (0.58, 2.79) \\ 1 \\ 0.91 (0.41, 1.93) \\ 1 \\ 1 \\ 0.87 (0.40, 1.88) \\ 1 \\ 2.06 (0.79, 5.36) \\ 2.0 (0.73, 5.51) \\ 1 \\ 1 \\ 0.12 (0.46, 0.31) \\ 1 \\ 1 \\ 8.33 (3.47, 19.98) \\ 1 \\ 1.62 (0.73, 3.58) \\ 1 \\ \end{array}$	
Ilone o alabia laval	<11 g/dl	16 (53.3%)	14 (46.7%)	8.33 (3.47, 19.98)	< 0.001
nemogrobin level	$\geq 11  \text{g/dl}$	162 (90.5%)	17 (9.5%)	$\begin{array}{c} 1\\ 1.65 \ (0.32, \ 8.39)\\ 1.62 \ (0.34, \ 7.5)\\ 1\\ 1.85 \ (0.86, \ 3.99)\\ 038 \ (0.09, \ 1.53)\\ 0.57 \ (0.22, \ 1.47)\\ 0.10 \ (0.10, \ 0.89)\\ 1\\ 0.732 \ (0.31, \ 1.71)\\ 1\\ 0.732 \ (0.31, \ 1.71)\\ 1\\ 0.732 \ (0.31, \ 1.71)\\ 1\\ 0.73 \ (0.10, \ 7.8)\\ 1.25 \ (0.57, \ 2.7)\\ 1\\ 0.57 \ (0.26, \ 1.26)\\ 1.24 \ (0.58, \ 2.79)\\ 1\\ 0.91 \ (0.41, \ 1.93)\\ 1\\ 0.87 \ (0.40, \ 1.88)\\ 1\\ 2.06 \ (0.79, \ 5.36)\\ 2.0 \ (0.73, \ 5.51)\\ 1\\ 1\\ 0.12 \ (0.46, \ 0.31)\\ 1\\ 1\\ 8.33 \ (3.47, \ 19.98)\\ 1\\ 1.62 \ (0.73, \ 3.58)\\ 1\\ \end{array}$	
MUAC	<23 cm	94 (82.5%)	20 (17.5%)	1.62 (0.73, 3.58)	0.230
MUAC	≥23 cm	84 (88.4%)	11 (11.6%)	1	

(\*) Ethiopian Birr, P value <0.05 statistically significant.

thrombocytopenic than their counterparts (AOR = 8.4, 95% CI = 1.86, 38, and P = 0.006), being anemic increase the likelihood of thrombocytopenia by eight times greater than that of nonanemic pregnant women (AOR = 8.3, 95% CI = 2.7, 25.6, and P < 0.01). A significantly greater prevalence of thrombocytopenia was observed in alcohol consumer participants (50%) than in nonalcohol consumer participants (AOR = 8.2, 95% CI = 2.17–31, P = 0.002).

#### 4. Discussion

Thrombocytopenia during pregnancy affects about 1 in 10 pregnant women worldwide. The rate of thrombocytopenia in pregnant women is 4 times greater than that in non-pregnant women. Therefore, timely diagnostic, preventive, and therapeutic measures are necessary for the effective management of thrombocytopenia during pregnancy [23].

Thrombocytopenia is the second most common hematologic disorder in the world and affects 7–10% of all pregnancies. This condition is responsible for up to 10% of postpartum hemorrhages in developing countries, for which the maternal mortality rate is 5.26% [15, 16].

The present study attempted to evaluate the magnitude of thrombocytopenia, severity patterns, and associated factors in pregnant women at Wachemo University Nigist Ellen Mohammed Memorial Compressive Specialized Hospital in southern Ethiopia. Our findings showed a 14.8% (95% CI: 10, 19.6) overall magnitude of thrombocytopenia among pregnant women; out of them, 24 (77.4%), 5 (16.1%), and 2 (6.5%) had mild, moderate, and severe thrombocytopenia, respectively.

Getawa et al. reported that the overall pooled prevalence of thrombocytopenia among pregnant women in Africa was 10.23% (CI = 7.44-13.02) [24]. The overall prevalence of

TABLE 4: Multivariate logistic regressions of selected factors associated with thrombocytopenia among pregnant women attending antenatal care clinics at Wachemo University Nigist Ellen Mohammed Comprehensive Specialized Hospital Hosanna, Southern Ethiopia, from June to August 30, 2022.

Variables	Catagorias	Thrombocytopenia		COB (050/ CI)		Drulus
variables	Categories	No (%)	Yes (%)	COR (95% CI)	AUK (95% CI)	P value
Residence	Urban	113 (88.3%)	15 (11.7%)	1		
	Rural	65 (80.2%)	16 (19.9%)	1.85 (0.86, 3.9)	2.6 (1.02, 7.12)	$0.045^{*}$
	Illiterate	24 (88.9%)	3 (11.1%)	0.38 (0.09, 1.5)	0.5 (0.08, 2.99)	0.459
Educational status	Primary school	59 (84.3)	11 (15.7)	0.57 (0.22, 1.4)	0.7 (0.19, 2.71)	0.640
Educational status	Secondary school	61 (9%)	6 (9%)	0.10 (0.10, 0.8)	0.40 (0.10, 1.64)	0.207
	College/university and above	34 (75.6%)	11 (24.4)	1		
Duraniana ANIC fallena an	Yes	85 (81.7%)	19 (18.3%)	1		
Previous ANC follow-up	No	93 (88.6%)	12 (11.4%)	0.57 (0.26, 1.26)	0.50 (0.19, 1.31)	0.162
Fat most and animal modulet	Yes	156 (86.7)	24 (13.3%)	1		
Eat meat and animal product	No	22 (75.9%)	7 (24.1%)	2.06 (0.7, 5.3)	0.34 (0.09, 1.12)	0.09
Smalring sizes note	Yes	12 (66.7%)	6 (33.3%)	3.32 (1.1, 9.6)	8.4 (1.86, 38)	0.006*
Smoking cigar rete	No	166 (86.9%)	25 (13.1%)	1		
	Yes	11 (50%)	11 (50%)	0.12 (0.4, 0.3)	8.2 (2.17, 31)	0.002*
Alcohol consumption	No	167 (89.3%)	20 (10.7%)	1		
II	<11 g/dl	16 (53.3%)	14 (46.7%)	8.33 (3.4, 19.9)	8.3 (2.7, 25.6)	< 0.001*
Hemoglobin level	$\geq 11 \text{ g/dl}$	162 (90.5%)	17 (9.5%)	1		
MUAC	<23 cm	94 (82.5%)	20 (17.5%)	1.62 (0.7, 3.58)	2.03 (0.72, 5.7)	0.23
	≥23 cm	84 (88.4%)	11 (11.6%)	1		
History of malaria	Yes	19 (76%)	6 (24%)	2.0 (0.73, 5.51)	1.3 (0.34, 4.8)	0.697
	No	159 (86.4%)	25 (13.6%)	1		

1.0 = Referent category, \*statistically associated P value <0.05, COR = crude odd ratio, AOR = adjusted odd ratio.

thrombocytopenia obtained in our study was consistent with studies done in Ethiopia 14.5% [21], 13.5% [3], and 10.2% [25], India 10.2% [26], Libiya 18% [27], Ghana 15.3% [5], Nigeria 13.5% [28], and Uganda 15.8% [15].

The present study showed a greater incidence of thrombocytopenia than the studies conducted in Ethiopia (7.7–9.9%) [17, 18, 29], India (8.8%) [30], Libya (8.3%) [31], and Baghdad (7.1%) [32]. The difference in the prevalence of thrombocytopenia might be due to differences in socio-demographics, sample size, variability of the automated analyzer, geographical variation, or lifestyle.

A systematic review and meta-analysis of global thrombocytopenia showed that the prevalence of thrombocytopenia is four times greater in pregnant women than in nonpregnant women [23]; the average global prevalence was 8.4% (CI: 6.9–10.1%) [23]. However, our study finding was higher than the global prevalence of thrombocytopenia. Therefore, these findings provide assurance or confirmation that routine screening and follow-up programs are needed to identify pregnant women with thrombocytopenia and offer them essential interventions.

Hematological changes during pregnancy are common and can lead to maternal and fetal morbidity, especially in the third trimester, when the condition is affected by thrombocytopenia. There are many causes of thrombocytopenia during pregnancy, ranging from mild to lifethreatening, and thrombocytopenia needs to be diagnosed and treated promptly [7, 17]. The severity patterns among the thrombocytopenic pregnant women in our study were 77.4%, 16.1%, and 6.5% in mild, moderate, and severe thrombocytopenia, respectively. These findings are consistent with studies conducted in Ethiopia, Libya, India, Uganda, and Ghana [3, 15, 19, 26, 31, 33, 34], which indicate a high frequency of mild thrombocytopenia.

Several studies have reported that the prevalence of thrombocytopenia is significantly affected by different sociodemographic characteristics [18, 21, 29]. In the present study, thrombocytopenia was significantly associated with rural residence. These findings are in agreement with those of studies performed in Ethiopia [33, 34] and Libya [31]. This might be related to a lack of information about adequate nutrition, lack of information on factors causing thrombocytopenia and possible strategies to prevent risk factors, inaccessibility of health care centers to ANC follow-up, and way of life.

Alcoholism is one of the most serious socioeconomic health problems in the world [35]. According to the current study, pregnant women with a habit of alcohol consumption were 8 times more likely to develop thrombocytopenia than their counterparts were. This finding was in line with a study in Ethiopia in which the habit of alcohol consumption was more likely to lead to thrombocytopenia [21]. The possible explanations that explain these associations might be the direct toxic effect of alcohol on the suppression of blood cell production, hematopoiesis, impaired function, and a decreased platelet life span [33, 35, 36].

Cigarette smoking can induce both acute and chronic effects on platelet function. Smoking induces oxidative stress, leading to increased platelet activation and aggregation and endothelial injury [37]. The present study

Advances in

revealed that there was a statistically significant association between thrombocytopenia and smoking cigarettes. Smoking cigarettes were associated with 8.4 times greater odds of thrombocytopenia than nonsmoking cigarettes were. A possible explanation might be that cigarette smoke induces oxidative stress, damages endothelial tissue, and disturbs the function of platelets, especially through activation and aggregation, as well as other coagulation components, leading to thrombosis [34, 37, 38].

Anemia during pregnancy was strongly associated with thrombocytopenia in this study. The odds of having thrombocytopenia were eight times higher among women with an Hb concentration less than 11 g/dl compared to those who had hemoglobin  $\geq 11$  g/dl, which are significant (A0R: 7.7 and 95% CI: 2.8-21.6). This finding was similar to that of a study performed in Uganda and Ethiopia, where a strong association between anemia and thrombocytopenia was observed [15, 39]. Recurrent thrombocytopenia has typically been linked to iron deficiency anemia, which is prevalent throughout pregnancy. The dual role of iron in the creation of platelets, which is necessary for the production of an integral section of the platelet, and the diphasic response of platelets to erythropoietin are the hypothesized causes of thrombocytopenia in patients with IDA [40]. The findings of our study should be concluded in light of some limitations. First, the cross-sectional nature of the study design prohibited the establishment of causal links between thrombocytopenia and factors that are significantly associated with thrombocytopenia. Second, the duration of alcohol consumption per day, type of alcohol, and alcohol concentration among the study participants were not assessed. Third, data on cigarette smoking concerning the number smoked per day and the type of cigarettes smoked were not assessed among the study participants.

#### 5. Conclusion

A greater magnitude of thrombocytopenia (14.8%) was observed among pregnant women. Among the thrombocytopenic pregnant women, mild thrombocytopenia was the predominant condition in our study. Rural residence, alcohol consumption, cigarette [41] smoking, and anemia were identified as independent predictors of thrombocytopenia among pregnant women. Therefore, screening should include platelet counts, especially when the woman is from a rural residence, is anemic, consumes alcohol, or is a cigarette smoker, to avoid adverse outcomes.

## **Data Availability**

All relevant data are in the manuscript. Additional data used to support the findings of this study are available from the corresponding author upon request.

#### Disclosure

Funders played no role in the decision to publish, manuscript preparation, and publication.

## **Conflicts of Interest**

The authors declare that they have no conflicts of interest.

#### Acknowledgments

The authors thank the staff and study participants for their important contributions. Jimma University sponsored this study.

# References

- Pregnancy practice bulletin thrombocytopenia, "Thrombocytopenia in pregnancy," *Clinical Management Guidelines for Obstetrician*, vol. 166, no. 3, pp. e43–e44, 2016.
- [2] K. J. Smock and S. L. Perkins, "Thrombocytopenia: an update," *The International Journal of Literary Humanities*, vol. 36, no. 3, pp. 269–278, 2014.
- [3] Z. Geto, A. Amsalu, and D. Daka, "Prevalence of thrombocytopenia, and associated factors among pregnant women in Hawassa, Ethiopia," *Journal of Harmonized Research in Medical and Health Science*, vol. 2, no. 4, pp. 175–182, 2015.
- [4] O. Erhabor, A. D. Muhammad, T. C. Adias, Y. Ahmed, and T. Erhabor, "Anaemia and thrombocytopenia among pregnant women attending aminu kano teaching hospital, kano state, north western Nigeria," *Human Antibodies*, vol. 28, no. 1, pp. 11–19, 2020.
- [5] E. Olayemi, "Gestational thrombocytopenia among pregnant Ghanaian Women," *Pan African Medical Journal*, vol. 1–7, p. 12, 2014.
- [6] A. Dangana, A. U. Emeribe, H. A. Isah et al., "Assessment of Platelet Indices Profile of Pregnant Women Attending University of Abuja Teaching Hospital, Nigeria," *Indonesian Journal of Medical Laboratory Science and Tehnology*, vol. 3, no. 2, pp. 99–108, 2021.
- [7] P. Patel and N. Balanchivadze, "Hematologic findings in pregnancy: a guide for the internist," *Cureus*, vol. 13, no. 5, Article ID e15149, 2021.
- [8] L. X. Zhang, N. Dong, R. X. Yang et al., "Platelet counts during pregnancy in Chinese women," *Journal of Laboratory Medicine*, vol. 44, no. 5, pp. 313–317, 2020.
- [9] B. Myers, "Diagnosis and management of maternal thrombocytopenia in pregnancy," *British Journal of Haematology*, vol. 158, no. 1, pp. 3–15, 2012.
- [10] A. Begam, S. Tl, B. Nambisan, and V. Kp, "Risk factors of thrombocytopenia in pregnancy," *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*, vol. 6, no. 2, p. 700, 2017.
- [11] N. Gaba and S. Gaba, "Etiology and fetomaternal outcomes of thrombocytopenia during pregnancy," *Perinatology*, vol. 21, no. 2, pp. 45–49, 2020.
- [12] R. P. Shamoon, N. S. Muhammed, and M. S. Jaff, "Prevalence and etiological classification of thrombocytopenia among a group of pregnant women in Erbil City, Iraq," *Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology*, vol. 26, no. 3, pp. 123–128, 2009.
- [13] C. M. Acog, "Clinical management guidelines for obstetrician

   gynecologists thrombocytopenia in pregnancy," Wolters Kluwer Health, vol. 133, no. 166, pp. 589–591, 2019.
- [14] R. Katke and D. Gohil, "Thrombocytopenia during pregnancy: an institutional based study," *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*, vol. 3, no. 4, p. 947, 2014.

- [15] D. Ruiru, S. Byonanuwe, and B. Oguttu, "And determinants of thrombocytopenia among women delivering at kampala international university teaching hospital, western Uganda," *Medical Journal of Obstetrics and Gynecology*, vol. 9, no. 1965, pp. 1–4, 2021.
- [16] M. N. M. Hamad, D. K. Idam, and H. A. Alshazali, "Prevalence of gestational thrombocytopenia among selected group of pregnant women attended to soba university hospital, Sudan, July-September 2016," *Women's Health*, vol. 7, no. 6, pp. 197–200, 2018.
- [17] A. Gebreweld, D. Bekele, and A. Tsegaye, "Hematological profile of pregnant women at st. Paul's hospital millennium medical college, Addis Ababa, Ethiopia," *BMC Hematology*, vol. 18, no. 1, pp. 15–17, 2018.
- [18] F. Asrie, B. Enawgaw, and Z. Getaneh, "Prevalence of thrombocytopenia among pregnant women attending antenatal care service at Gondar University teaching hospital in 2014, northwest Ethiopia," *Journal of Blood Medicine*, vol. 8, pp. 61–66, 2017.
- [19] S. F. C. Subtil, J. M. B. Mendes, A. L. F. D. A. Areia, and J. P. A. S. Moura, "Update on thrombocytopenia in pregnancy," *Revista Brasileira de Ginecologia e Obstetrícia RBGO Gynecology and Obstetrics*, vol. 42, no. 12, pp. 834–840, 2020.
- [20] P. Salaj, "Congenital and acquired bleeding disorders," *Vnitrní Lékarství*, vol. 64, no. 5, pp. 547–558, 2018.
- [21] K. Haile, S. Kebede, T. Abera, A. Timerga, and A. Mose, "Thrombocytopenia among pregnant women in southwest Ethiopia: burden, severity, and predictors," *Journal of Blood Medicine*, vol. 13, no. May, pp. 275–282, 2022.
- [22] Erkurt, "Thrombocytopenia in adults: review article," *Journal* of Hematology, vol. 1, pp. 44–53, 2012.
- [23] M. Mohseni, Z. Asgarlou, S. Azami-Aghdash, S. Sheyklo, N. Tavananezhad, and A. Moosavi, "The global prevalence of thrombocytopenia among pregnant women: a systematic review and meta-analysis," *Nursing and Midwifery Studies*, vol. 8, no. 2, pp. 57–63, 2019.
- [24] S. Getawa, Z. Getaneh, and M. Melku, "Thrombocytopenia among pregnant women in Africa: a systematic review and meta-analysis," *Pan African Medical Journal*, vol. 41, no. 334, pp. 1–15, 2022.
- [25] D. Shitie, T. Zewde, and Y. Molla, "Anemia and other hematological profiles of pregnant women attending antenatal care in Debre Berhan Referral Hospital, North Shoa," *BMC Research Notes*, vol. 11, no. 704, pp. 1–7, 2018.
- [26] J. Resident, "Prevalence and clinic-etiologic profile of thrombocytopeniain pregnancy," *International Journal of Medical and Biomedical Studies*, vol. 4, no. July 2016, pp. 213–215, 2020.
- [27] S. Muspah and S. Altayri, "Prevalence of thrombocytopenia among pregnant women in tripoli region, Libya," *Scientific Publications*, vol. 1, no. 1, pp. 23–28, 2017.
- [28] S. Ajibola, A. Akinbami, A. Dosunmu et al., "Gestational thrombocytopaenia among pregnant women in Lagos, Nigeria," *Nigerian Medical Journal*, vol. 55, no. 2, p. 139, 2014.
- [29] H. Ebrahim, B. Kebede, M. Tilahun, H. Debash, H. Bisetegn, and M. Tesfaye, "Magnitude and associated factors of thrombocytopenia among pregnant women attending antenatal care clinics at dessie comprehensive specialized hospital, northeast Ethiopia," *Clinical and Applied Thrombosis*, vol. 28, pp. 107602962210973–107602962210978, 2022.
- [30] S. Nisha, D. Amita, S. Uma, A. K. Tripathi, and S. Pushplata, "Prevalence and characterization of thrombocytopenia in pregnancy in Indian women," *Indian Journal of Hematology* and Blood Transfusion, vol. 28, no. 2, pp. 77–81, 2012.

- [31] A. Atia and N. Omar, "Prevalence of thrombocytopenia during pregnancy among Libyan women Prevalence of thrombocytopenia during pregnancy among Libyan women," *Mediterranean Journal of Pharmacy and Pharmaceutical Sciences*, vol. 2, no. August, pp. 21–24, 2021.
- [32] E. M. Muhammad, E. H. Sabri, and H. D. Saeed, "The prevalence of thrombocytopenia in pregnant women in Baghdad: single centre study," *Journal of the Faculty of Medicine, Baghdad*, vol. 60, no. 2, pp. 98–101, 2018.
- [33] A. Silczuk and B. Habrat, "Alcohol-induced thrombocytopenia: current review," *Alcohol*, vol. 86, pp. 9–16, 2020.
- [34] M. Pujani, V. Chauhan, K. Singh, S. Rastogi, C. Agarwal, and K. Gera, "The effect and correlation of smoking with platelet indices, neutrophil lymphocyte ratio and platelet lymphocyte ratio," *Hematology, Transfusion and Cell Therapy*, vol. 43, no. 4, pp. 424–429, 2021.
- [35] P. Sammaiah, R. Prasad, and V. C. Shekhar, "Study of haematological manifestations, among alcoholics in tertiary care hospital," *International Journal of Scientific Study*, vol. 6, no. 3, pp. 6–11, 2018.
- [36] A. Hasb, "The hematological complications of alcoholism," *Alcohol Health and Research World*, vol. 21, pp. 93–6.
- [37] H. H. Mundal, P. Hjemdahl, and K. Gjesdal, "Acute effects of cigarette smoking on platelet function and plasma catecholamines in hypertensive and normotensive men," *American Journal of Hypertension*, vol. 11, no. 6, pp. 677–681, 1998.
- [38] F. Ghahremanfard, V. Semnani, R. Ghorbani, F. Malek, A. Behzadfar, and M. Zahmatkesh, "Effects of cigarette smoking on morphological features of platelets in healthy men," *Saudi Medical Journal*, vol. 36, no. 7, pp. 847–850, 2015.
- [39] F. Belayneh, F. Solomon, Z. Geto, A. Amsalu, D. Daka, A. Ababa et al., "Prevalence of thrombbocytopenia, and associated factors among pregnant in Hawassa, Ethiopia," *Journal of Harmonized Research in Medical and Health Science*, vol. 2, no. 4, pp. 175–182, 2015.
- [40] B. J. Hassan and M. P. Campos, "Iron deficiency thrombocytopenia: a case report and review of the literature," *Journal* of Clinical Case Reports, vol. 08, no. 03, pp. 8–10, 2018.